Achievement 2005 2006 General v 2005 revenues 372

Achievement 2005 -2006 —General v 2005 revenues: 372 million USD 2006 YTD (Sep. ): 300 million USD 8%Growth v The largest manufacturer and supplier of Vaccines in China , supply 95% EPI Vaccine for China. Over 800 million doses of various vaccines in 2005 v The largest manufacturer and supplier of Blood Derivatives in China v Products export to over 30 countries JEV: India, Korea, Nepal. v New Product: 23 -valent Pneumococcal Polysaccharide Vaccine Apr. 2006 licensed Freeze-dried Vero Rabies vaccine Nov. 2005 licensed

Achievement 2005 -2006 —R&D v Projects for Vaccines, Blood derivatives, Biopharmaceuticals, Diagnosis Reagents, etc. . - 18 projects in state level - 3 projects for industrialization. - 9 projects got SFDA approval of New Drug Application. v 15 preclinical studies completed, while 9 clinical trials conducted. v Intellectual patents: 4 Chinese, 3 international, 49 in process. v National New Vaccine Engineering Center established in Beijing.

Achievement 2005 -2006 —New Facilities v JEV facilities — Chengdu v 23 -valent PPV facilities — Chengdu v Blood Derivatives facilities — Chengdu (accomplished) v DTa. P facilities — Wuhan (accomplished) v Bacterial Vaccine Building — Lanzhou v SPF Animal Building — Lanzhou v R&D Building — Shanghai v R&D Building of National Vaccine Engineering Center— Beijing

Achievement 2005 -2006 —Awards v SARS pathology and the development of SARS control and prevention system the second prize of National Awards for Progress in Science & Technology for the research in 2005 v National Key New Product Freeze-dried Measles & Mumps combined vaccine, Live. Hib conjugate vaccine. Split Influenza vaccine.